These codes are used to report injectable drugs that ordinarily cannot be self-administered; chemotherapy, immunosuppressive drugs and inhalation solutions as well as some orally administered drugs.

View All HCPCS Sections

• J9021

  Injection, asparaginase, recombinant, (rylaze), 0.1 mg

• J9022

  Injection, atezolizumab, 10 mg

• J9023

  Injection, avelumab, 10 mg

• J9024

  Injection, atezolizumab, 5 mg and hyaluronidase-tqjs

• J9025

  Injection, azacitidine, 1 mg

• J9026

  Injection, tarlatamab-dlle, 1 mg

• J9027

  Injection, clofarabine, 1 mg

• J9028

  Injection, nogapendekin alfa inbakicept-pmln, for intravesical use, 1 microgram

• J9029

  Intravesical instillation, nadofaragene firadenovec-vncg, per therapeutic dose

• J9030

  Bcg live intravesical instillation, 1 mg

• J9031

  Bcg (intravesical) per instillation

• J9032

  Injection, belinostat, 10 mg

• J9033

  Injection, bendamustine hydrochloride, 1 mg

• J9034

  Injection, bendamustine hcl (bendeka), 1 mg

• J9035

  Injection, bevacizumab, 10 mg

• J9036

  Injection, bendamustine hydrochloride, (belrapzo/bendamustine), 1 mg

• J9037

  Injection, belantamab mafodotin-blmf, 0.5 mg

• J9038

  Injection, axatilimab-csfr, 0.1 mg

• J9039

  Injection, blinatumomab, 1 microgram

• J9040

  Injection, bleomycin sulfate, 15 units

• J9041

  Injection, bortezomib, 0.1 mg

• J9042

  Injection, brentuximab vedotin, 1 mg

• J9043

  Injection, cabazitaxel, 1 mg

• J9044

  Injection, bortezomib, not otherwise specified, 0.1 mg

• J9045

  Injection, carboplatin, 50 mg

• J9046

  Injection, bortezomib (dr. reddy's), not therapeutically equivalent to j9041, 0.1 mg

• J9047

  Injection, carfilzomib, 1 mg

• J9048

  Injection, bortezomib (fresenius kabi), not therapeutically equivalent to j9041, 0.1 mg

• J9049

  Injection, bortezomib (hospira), not therapeutically equivalent to j9041, 0.1 mg

• J9050

  Injection, carmustine, 100 mg

• J9051

  Injection, bortezomib (maia), not therapeutically equivalent to j9041, 0.1 mg

• J9052

  Injection, carmustine (accord), not therapeutically equivalent to j9050, 100 mg

• J9054

  Injection, bortezomib (boruzu), 0.1 mg

• J9055

  Injection, cetuximab, 10 mg

• J9056

  Injection, bendamustine hydrochloride (vivimusta), 1 mg

• J9057

  Injection, copanlisib, 1 mg

• J9058

  Injection, bendamustine hydrochloride (apotex), 1 mg

• J9059

  Injection, bendamustine hydrochloride (baxter), 1 mg

• J9060

  Injection, cisplatin, powder or solution, 10 mg

• J9061

  Injection, amivantamab-vmjw, 2 mg

• J9063

  Injection, mirvetuximab soravtansine-gynx, 1 mg

• J9064

  Injection, cabazitaxel (sandoz), not therapeutically equivalent to j9043, 1 mg

• J9065

  Injection, cladribine, per 1 mg

• J9070

  Cyclophosphamide, 100 mg

• J9071

  Injection, cyclophosphamide (auromedics), 5 mg

• J9072

  Injection, cyclophosphamide (frindovyx), 5 mg

• J9073

  Injection, cyclophosphamide (dr. reddy's), 5 mg

• J9074

  Injection, cyclophosphamide (sandoz), 5 mg

• J9075

  Injection, cyclophosphamide, not otherwise specified, 5 mg

• J9076

  Injection, cyclophosphamide (baxter), 5 mg

---

HCPCS Level II codes and descriptors are approved and maintained jointly by the alpha-numeric editorial panel (consisting of CMS, the Health Insurance Association of America, and the Blue Cross and Blue Shield Association). — Updated 6/4/2026

CPT^® is a registered trademark of the American Medical Association (AMA). All rights reserved.